Inovio Pharmaceuticals, Inc.

NASDAQ:INO

Biotechnology

Healthcare
$1.69 -0.90%

-$0.01 today

Market cap
$116.77M
Beta
1.49
P/E (TTM)
-8.9
EPS (TTM)
-$0.12
52W Low $1.03High $2.98

Volume 11.56M

Average 2.73M

INO Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Inovio Pharmaceuticals, Inc.NASDAQ: INO

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables remains negative

Q1 FY2026 net receivables was $0, compared with $1.31M a year earlier. Over 3 fiscal years it compounded at -96.6% a year.

Context

  • Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026, down 1.5 pp from a year earlier.
  • Net receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$450-100.0% YoY
Year agoMar 2025
$1.31M-100.0% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR-96.6%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
450 USD
Year-over-year change
-100.0%
4-year CAGR
-91.3%

Net Receivables vs competitors

How INO compares with its peers on the latest reported figures

  • INO's Mar 2026 net receivables of $0 is the 8th highest of the 10 companies compared; the peer median is $704K.
  • Its year-over-year change of -100.0% is the lowest of 8, against a peer median of -42.9%.
  • Net receivables amounts to 0.0% of total assets for INO, versus a peer median of 0.2%.
INO Competitors Peer median
Net Receivables for INO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AGENAgenus Inc.Mar 2026$54.06M +15171.8%-12.6%29.0%
SEERSeer, Inc.Mar 2026$4.26M -20.5%-5.3%1.6%
IRDOpus Genetics, Inc.Mar 2026$2.72M -42.9%-13.3%4.1%
ABOSAcumen Pharmaceuticals, Inc.Mar 2026$772K +105.3%—0.6%
FATEFate Therapeutics, Inc.Mar 2026$704K -70.7%-71.2%0.2%
MCRBSeres Therapeutics, Inc.Mar 2026$233K -94.7%—0.2%
SPROSpero Therapeutics, Inc.Mar 2026$44K -99.8%+186.1%0.1%
INOInovio Pharmaceuticals, Inc.Mar 2026$0 -100.0%-96.6%0.0%
ALECAlector, Inc.Mar 2026$0 ——0.0%
ACTUActuate Therapeutics IncMar 2026$0 ——0.0%
Peer median (excluding INO) $704K-42.9%-12.6%0.2%

Competitors are the stored peer set for INO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents71.14M46.33M14.31M65.81M44.27M
Short-term Investments330.17M206.67M130.98M28.3M14.24M
Net Receivables8.03M11.74M2.41M1.2M450
Inventory00000
Other Current Assets261.19K30.38M20.43K00
Total Current Assets448.44M315.24M153.11M97.83M61.12M
Property, Plant & Equipment (Net)29.02M17.96M14.45M11.77M9.07M
Goodwill10.51M10.51M000
Intangible Assets2.63M2.13M000
Long-term Investments3.91M2.01M2.78M1.61M2.1M
Tax Assets00000
Other Non-current Assets1.43M684.04K605.32K1.98M2.01M
Total Non-current Assets47.5M33.29M17.84M15.37M13.19M
Total Assets495.94M348.53M170.95M113.2M74.31M
Account Payables27.97M21.08M4.65M6.44M2.62M
Short-term Debt0016.77M00
Tax Payables00000
Deferred Revenue21.63K0000
Other Current Liabilities20.71M15.14M9.95M23.26M36.44M
Total Current Liabilities65.74M96.87M42.57M35.33M43.67M
Long-term Debt14.96M16.61M000
Deferred Tax Liabilities32.05K32.05K000
Deferred Revenue (Non-current)64.36K0000
Other Non-current Liabilities14.83K0000
Total Non-current Liabilities30.53M29.3M11.03M9.37M6.55M
Total Liabilities96.27M126.17M53.6M44.69M50.21M
Common Stock217.38K21.09K22.79K36.1K69K
Retained Earnings(1.21B)(1.49B)(1.62B)(1.73B)(1.82B)
Accumulated OCI(282.24K)(698.74K)(662.6K)(675.67K)(637.96K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity399.67M222.36M117.35M68.5M24.1M
Total Debt33.02M32.07M30.21M11.87M9.37M
Net Debt(38.12M)(14.25M)15.9M(53.95M)(34.91M)

Inovio Pharmaceuticals, Inc.

NASDAQ:INO

Intrinsic Alpha fair value

Locked

Current Price

$1.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.